For Immediate Release
Chicago, IL – October 19, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include
Novartis ( NVS Quick Quote NVS - Free Report) , Zoom Video Communications ( ZM Quick Quote ZM - Free Report) , Fidelity National Information Services ( FIS Quick Quote FIS - Free Report) , 3M Company ( MMM Quick Quote MMM - Free Report) and TOTAL SE ( TOT Quick Quote TOT - Free Report) . Here are highlights from Friday’s Analyst Blog: Top Research Reports for Novartis, Zoom Video and Fidelity Information Services
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis, Zoom Video Communications and Fidelity National Information Services. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>> Novartis shares have underperformed the Zacks Large-Cap Pharmaceuticals in the year to date period (-9.9% vs. -2.3%). The Zacks analyst believes that solid performance of key drugs like Cosentyx and Entresto, and contributions from Kisqali and gene therapy, Zolgensma, have also boosted the company’s performance in the recent past.
These drugs and new launches like Piqray, Mayzent and Beovu should further boost sales amid a slowdown due to the ongoing pandemic. The biosimilar portfolio also gains traction with new key approvals and is expected to drive growth. Novartis’ efforts to develop and diversify its pipeline are also impressive.
However, price erosion in the United States has adversely impacted the generics business. Moreover, pipeline setbacks and generic competition for key drugs are concerning. Shares have underperformed the industry in the past year. The company has tightened its outlook for 2020 due to the pandemic woes.
) read the full research report on Novartis here >>>
Zoom Video have gained +734.8% over the past year against the Zacks Internet Software industry’s rise of 93.8%. The Zacks analyst believes that demand for the company’s cloud-native video-first platform is expected to remain solid owing to the work-from-home and online-learning wave.
Easy to deploy, use, manage and scalability makes Zoom Video’s software popular among its customers. Expanding clientele is expected to drive top-line growth momentum in the near term. Moreover, the company’s expanding international presence is a key catalyst.
Its efforts to eliminate the security and privacy loopholes, as well as new hardware and Zoom From Home solution’s launch, are expected to help in expanding clientele. The company’s strong free cash-flow generating ability is noteworthy. However, acute competition from the likes of Microsoft and Cisco in the video-communication space does not bode well.
) read the full research report on Zoom Video here >>> FIS shares have gained +14% over the past six months against the Zacks Financial Transaction Services industry’s rise of +19.1%. The Zacks analyst believes that the company remains well-poised for growth, backed by attractive core business with several ongoing initiatives and a broad customer base.
The acquisition of Worldpay will accelerate growth by expanding presence in fast-growing markets. Further, increasing investment in mobile banking and innovative products is likely to support Fidelity's growth.
Also, earnings estimates have been going down lately ahead of third-quarter results. The company remains exposed to rising costs on account of investment in technology, and consolidation in the banking sector. It faces credit risk in case of any economic downturn.
) read the full research report on FIS here >>>
Other noteworthy reports we are featuring today include 3M Company and TOTAL SE.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>
Join us on Facbook:
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.